News

Some medical specialists lack awareness of systemic mastocytosis (SM) because of its association with various symptoms.

Avapritinib significantly improved overall survival in patients with SM compared to midostaurin or best available therapy.

Patients with systemic mastocytosis (SM) have a different plasma protein profile compared to healthy people.

Preliminary results showed that patients receiving bezuclastinib had better results than patients receiving a placebo in a clinical trial.

RNA-based testing significantly enhanced the detection of KIT mutations, which is critical for diagnosing systemic mastocytosis.

A new study will examine a treatment for patients with systemic mastocytosis with an associated hematologic neoplasm.

Imatinib is a treatment for patients with aggressive SM without the KIT D816V mutation or having unknown KIT mutational status.

A 100 mg dose reduced mast cell burden, alleviated debilitating symptoms and improved quality of life compared to placebo.

A new prognostic score confirmed that KIT Inhibitors improve outcomes in patients with advanced systemic mastocytosis (SM).

A new model accurately distinguished between advanced and indolent systemic mastocytosis using blood sample parameters.